MISSION Therapeutics has attracted one of the highest profile syndicates of investors in Europe. The Company has to date received £87 million in venture capital from a blue chip syndicate of institutional and corporate investors.
In 2011 a Series A £6m funding was led by Sofinnova Partners, together with Imperial Innovations, SR One and the Roche Venture Fund. In 2013, the Company closed a £20m ($32m) Series B equity financing with follow-on investment from all the existing shareholders plus a new investor, Pfizer Venture Investments.
In February 2016, MISSION closed a £60 million Series C funding round led by Imperial Innovations and new investor Woodford Patient Capital Trust with follow-on investment from existing shareholders Sofinnova Partners, SR One, Roche Venture Fund and Pfizer Venture Investments.
Sofinnova Partners is an independent venture capital firm based in Paris, France. For 40 years, the firm has backed nearly 500 companies at different stages of their development – pure creations, spin-offs, as well as turnaround situations – and worked alongside Europe’s key entrepreneurs in the Life Sciences and Clean Energy sectors. With €1.3 billion of funds under management, Sofinnova Partners’ experienced team and hands-on approach in building portfolio companies through to exit have created market leaders, from landmark historical investments including Genentech and Actelion to more recent successes such as Corevalve, Novexel, Fovea, Movetis and Preglem. With a global mindset, the firm has a sister organisation in San Francisco, California. For more information, please visit http://www.sofinnova.fr
Imperial Innovations creates, builds and invests in pioneering technologies addressing global problems in healthcare, energy, engineering and the environment. It combines deep understanding of science and technology with commercial acumen and strong investment expertise, and supports scientist-entrepreneurs in the commercialisation of their ideas. In December 2010 Innovations raised £140 million to accelerate the making of, and increase the size of, investments in companies established under its existing intellectual property pipeline agreement with Imperial College London. The Group also invests in companies founded by or based on technology from the University of Oxford, the University of Cambridge and University College London. For more information, please visit http://www.imperialinnovations.co.uk
SR One is the independent corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. Since 1985, SR One has invested in more than 150 companies and has a current portfolio of approximately 30 private and public companies. For more information, please visit www.srone.com
Roche Venture Fund
The Roche Venture Fund invests in early stage biotech and diagnostics companies to develop commercially successful innovative life science companies. Based in Basel, Switzerland with an office in South San Francisco, the Roche Venture Fund invests globally with a portfolio of over 35 companies in 10 countries. For more information, please visit www.venturefund.roche.com
Pfizer Venture Investments
Pfizer Venture Investments (PVI), the venture capital arm of Pfizer Inc., was founded in 2004 and invests for return in areas of current or future strategic interest to Pfizer. As part of Worldwide Business Development, PVI seeks to remain at the forefront of life sciences advances, looking to identify and invest in emerging companies that are developing compounds and technologies that have the potential to enhance Pfizer’s pipeline and shape the future of the pharmaceutical industry. PVI invests in companies at any stage of development, with a strong focus on growth-stage opportunities, and is actively seeking to make new investments in a broad array of healthcare-related areas, including therapeutics, platform technologies, diagnostics, drug delivery, pharmaceutical services, healthcare IT, and other technologies impacting drug discovery and development. For more information, please visit www.pfizer.com
Woodford Patient Capital Trust
Woodford Patient Capital Trust is the £800 million investment trust launched in April 2015 by Woodford Investment Management LLP (“Woodford”). The trust invests mainly in early-stage and early-growth companies but also has exposure to some blue-chip companies. Woodford is a fast-growing asset management company built on a founding philosophy of transparency and simplicity. Launched in May 2014, Woodford Investment Management LLP has more than £14bn assets under management. For more information, please visit https://woodfordfunds.com